Mike Mensinger Sells 2,650 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 2,650 shares of the business’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total transaction of $58,300.00. Following the completion of the sale, the insider directly owned 177,390 shares in the company, valued at approximately $3,902,580. This represents a 1.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mike Mensinger also recently made the following trade(s):

• On Wednesday, September 2nd, Mike Mensinger sold 4,375 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total value of $83,606.25.

Beta Bionics Stock Down 3.4%

Shares of NASDAQ BBNX traded down $0.75 during trading on Thursday, reaching $21.43. The company had a trading volume of 3,089,176 shares, compared to its average volume of 1,193,079. The company’s fifty day moving average price is $17.46 and its 200-day moving average price is $13.93. Beta Bionics, Inc. has a 12 month low of $8.80 and a 12 month high of $32.71. The stock has a market cap of $964.14 million, a P/E ratio of -12.99 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $32.01 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. As a group, equities analysts predict that Beta Bionics, Inc. will post -2.05 earnings per share for the current year.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The U.S. FDA cleared Beta Bionics’ Mint patch pump, expanding the company’s diabetes-device portfolio beyond the iLet Bionic Pancreas. A full U.S. launch is planned for the first quarter of 2027, creating a potential additional growth driver. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: Analysts and market coverage have highlighted the Mint clearance as a step toward a broader, multi-product growth strategy. Recent earnings-estimate trends and a price-target increase from Bank of America also supported buying interest. Beta Bionics Shares Rise After BofA Price-Target Boost
• Positive Sentiment: Beta Bionics priced a public offering expected to raise approximately $150 million. The proceeds could fund Mint commercialization, manufacturing expansion, research and development, and working capital, improving financial flexibility. Beta Bionics Announces Pricing of Public Offering
• Neutral Sentiment: The offering includes 7.65 million common shares and pre-funded warrants for approximately 1.04 million additional shares, with a potential underwriters’ option for 1.30 million more shares. The capital raise strengthens the balance sheet but increases the potential share count.
• Negative Sentiment: Multiple law firms are publicizing a securities class action against Beta Bionics. The litigation alleges that management understated the significance of FDA Form 483 findings, a subsequent warning letter, quality-management issues, and unreported customer complaints. Investors have until November 3, 2026, to seek lead-plaintiff status; the allegations have not been proven. BBNX Shareholder Alert
• Negative Sentiment: Beta Bionics’ updated 2026 revenue outlook of $121 million to $126 million is below the roughly $133.9 million consensus estimate, raising concerns about near-term execution and commercialization. The equity offering may also weigh on the stock through dilution.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Weiss Ratings raised shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Truist Financial restated a “buy” rating and set a $23.00 target price (up from $22.00) on shares of Beta Bionics in a research report on Tuesday. Robert W. Baird raised their target price on Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Tuesday. The Goldman Sachs Group lifted their target price on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Bank of America boosted their price target on Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Tuesday. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Beta Bionics has a consensus rating of “Moderate Buy” and an average target price of $21.90.

Institutional Investors Weigh In On Beta Bionics

Several hedge funds and other institutional investors have recently bought and sold shares of BBNX. Caitong International Asset Management Co. Ltd raised its holdings in Beta Bionics by 1,075.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after buying an additional 1,818 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Beta Bionics in the second quarter valued at $62,000. ProShare Advisors LLC acquired a new position in shares of Beta Bionics during the fourth quarter valued at about $217,000. The Manufacturers Life Insurance Company acquired a new position in shares of Beta Bionics during the second quarter valued at about $172,000. Finally, Values First Advisors Inc. increased its position in shares of Beta Bionics by 35.1% during the first quarter. Values First Advisors Inc. now owns 47,551 shares of the company’s stock worth $476,000 after acquiring an additional 12,360 shares in the last quarter.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.